Emerging Treatment Strategies for CSU
This module explores novel CSU therapies, including BTK and IL-4/13 inhibitors, and mast cell-targeting agents. We will assess their efficacy and safety to determine their role in addressing unmet needs for patients with uncontrolled CSU.
Thomas B. Casale, MD FAAAAI
Professor of Medicine and Pediatrics
University of South Florida
Morsani College of Medicine
Tampa, FL
Dr Casale is Professor of Medicine at the University of South Florida in Tampa. He is a Past President of the AAAAI and was Executive Vice President for 10 years. He has served on the board of directors for ATS, WAO, and ABAI and was Chief Medical Advisor of FARE for 4 years. He has worked on bench to bedside research with a special focus on biologics and translational research. He has published over 550 scientific papers and been on editorial boards of multiple journals. He is recognized as one of the world’s top 2% most influential scientists by research.com.
1.
EVALUATE the efficacy and safety data for novel therapies for CSU to determine the appropriate use and place in therapy for patients with CSU
